What Evoq Technologies does

Evoq Technologies Corp is a privately held medical device company (Delaware corporation, Henderson, Nevada HQ, founded 2023 with operational lineage through Xenotec and OcuScience) that designs and sells smartphone-based wearable biosensor diagnostic devices for early detection of retinal dysfunction. Its product portfolio centers on the SmartERG® smartphone electrophysiology platform (FDA approval received November 2024), the Twilight™ FDA-registered Class I dark adaptometer (launched November 2025), and the SightGard™ platform that integrates these functional tests into routine eye care workflows for conditions including age-related macular degeneration, diabetic eye disease, and inherited retinal diseases.

The underlying technology replaces legacy desktop ERG and dark-adaptation instruments with portable, technician-led hardware paired to a smartphone, marketed to MD, OD, PhD, and DVM researchers and clinicians as a cost-effective alternative for evoked-response electrophysiology spanning vision, auditory, neurology, and physical therapy applications. The company holds FDA Operator Number 10083427 and is pursuing investigator-led clinical validation studies through its Scientific Advisory Board.

Evoq generates revenue primarily through direct hardware sales via its Shopify storefront (evoqtech.myshopify.com) and is actively soliciting licensing and partnership deals with medical device, pharmaceutical, and health delivery partners. Go-to-market mixes e-commerce, conference-driven field sales (ARVO, AAO, Vision Expo), and relationship development with healthcare providers. The company operates only in the United States today, has 11–50 employees, and discloses no revenue, funding rounds, or capital structure in the available data.

Name

Evoq Technologies

Legal name

Evoq Technologies Corp

Website

https://evoqtechnologies.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Evoq Technologies Corp is a privately held medical device company that builds smartphone-based wearable biosensor diagnostics — including the FDA-cleared SmartERG platform, Twilight dark adaptometer, and SightGard platform — to enable early detection of retinal dysfunction for eye care professionals, researchers, and at-risk patients in the United States.

Ownership category

akta.pro rank

Product category

Ophthalmic Diagnostic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515), Other Measuring and Controlling Device Manufacturing (334519)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Instruments For Meas & Testing Of Electricity & Elec Signals (3825), Optical Instruments & Lenses (3827), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

akta.pro secondary industries

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE), Sensors, MEMS & Imaging ICs (HDAHAAAG), Optical & Light Sensors (Photodiodes/ALS/Color/UV) (HDAHALAE)

Keywords

• Ophthalmic diagnostic devices
• Medical-grade biosensors
• Retinal electrophysiology
• Dark adaptometry
• Wearable medical devices

Headquarters

HQ city

Henderson

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Evoq Technologies generates revenue through the sale of FDA-registered medical devices including the SmartERG platform and Twilight Dark Adaptometer. Products are sold directly through the company's e-commerce storefront and are available for purchase in the United States.
2. Licensing and Partnerships: Evoq Technologies seeks licensing and partnership opportunities with medical device, pharmaceutical, and health delivery stakeholders who want to lead the future in function-first diagnostics. The company is open to licensing its proprietary technology platforms.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Evoq Technologies develops and sells FDA-registered medical-grade wearable biosensor diagnostic devices for early detection of retinal dysfunction. Its core offerings include the Twilight™ Dark Adaptometer (Class I medical device) and the SmartERG® smartphone-based electrophysiology system, unified under the SightGard™ platform, enabling portable, technician-led functional vision testing in clinical and home settings as a cost-effective alternative to legacy desktop ERG equipment.

Product overview

Evoq Technologies offers a portfolio of medical-grade wearable biosensor diagnostic devices and platforms focused on early detection of retinal dysfunction and vision diseases. The core product lineup includes the Twilight™ Dark Adaptometer (FDA-registered Class I device for dark adaptation testing), the SmartERG® smartphone-based electrophysiology system (FDA-registered), and the SightGard™ platform integrating functional testing into routine care. The SightGard platform serves as the overarching diagnostic framework, with Twilight and SmartERG representing the specific device families within it.

Differentiator

Problem solved

Functional benefit

Brands

• Twilight: FDA-registered Class I medical device for dark adaptation testing in eye care diagnostics
• SmartERG
• SightGard

Products and services

• Twilight™ Dark Adaptometer FDA-registered Class I medical device that performs dark adaptation tests faster and without specialized dark rooms, enabling earlier detection of visual dysfunction related to age-related macular degeneration (AMD), diabetic eye disease, and inherited retinal diseases; sold to eye care professionals and available direct to consumers via the company's e-commerce storefront in the United States.
• SmartERG® Smartphone-Based Electrophysiology System FDA-approved smartphone-based electrophysiology system that tests retinal health and supports evoked response electrophysiology for vision, auditory, neurology, and physical therapy applications; positioned as a cost-effective, portable alternative to legacy desktop electrophysiology devices for MD, OD, PhD, and DVM researchers, technologists, and clinicians.

Quantifiable outcome

• Twilight enables fast, technician-led dark adaptation tests in any clinical setting without specialized dark rooms
• +2 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Konan Medical: Konan Medical (which acquired LKC Technologies' dark adaptometry line) provides specialty ophthalmic diagnostic devices including dark adaptometers and electrophysiology tools, directly comparable to Evoq's Twilight and SmartERG.
• LKC Technologies: LKC Technologies manufactures the AdaptDx dark adaptometer and other visual electrophysiology devices used in AMD detection. It directly competes with Evoq's Twilight Dark Adaptometer in the dark adaptation and ERG market.
• Diopsys: Diopsys is a U.S. medical device company specializing in visual electrophysiology, including ERG and VEP systems used in ophthalmology and optometry. It is the most direct competitor to Evoq's SmartERG in clinical electrophysiology diagnostics.
• Diagnosys LLC: Diagnosys is a direct peer in visual electrophysiology, providing desktop and clinical ERG, VEP, and dark adaptation systems for ophthalmology research and clinical use. Overlaps with Evoq's evoked response and dark adaptation offerings.

Broad incumbents

• Heidelberg Engineering: Heidelberg Engineering is a major ophthalmic diagnostic incumbent selling OCT, perimetry, and imaging systems. It competes indirectly by bundling diagnostic modalities and could extend into portable ERG/dark adaptation, posing a competitive threat to Evoq's niche.
• Reichert Technologies (AMETEK): Reichert, part of AMETEK, manufactures ophthalmic diagnostic instruments including tonometers, refractors, and lensometers. It is a broad incumbent in clinical eye diagnostics with overlap in functional testing categories.
• iCare (including CenterVue): iCare (which acquired CenterVue) makes fundus imaging, perimetry, and tonometry devices for ophthalmology. It is a broad incumbent with adjacent functional testing products relevant to Evoq's diagnostic positioning.
• Topcon Healthcare: Topcon Healthcare is a global ophthalmic device incumbent offering imaging, perimetry, and diagnostic instruments. It is a broad incumbent whose portfolio overlaps with the diagnostic categories Evoq is targeting.
• Carl Zeiss Meditec: Carl Zeiss Meditec is one of the largest ophthalmic device companies globally, offering OCT, perimetry, and other diagnostic systems. It is a broad incumbent whose resources dwarf Evoq's and could enter portable electrophysiology.
• Nidek Co., Ltd. Nidek is a Japanese ophthalmic equipment manufacturer offering a wide range of diagnostic and refractive devices. Comparable as a broad incumbent in ophthalmic diagnostics that could expand into portable ERG or dark adaptation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/smarterg

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evoq Technologies